RS

ReShape Lifesciences IncNASDAQ RSLS Stock Report

Last reporting period 30 Jun, 2024

Updated 14 Nov, 2024

Last price

Market cap $B

0.005

Micro

Exchange

XNAS - Nasdaq

RSLS Stock Analysis

RS

Uncovered

ReShape Lifesciences Inc is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

24/100

Low score

Market cap $B

0.005

Dividend yield

Shares outstanding

0.519 B

ReShape Lifesciences, Inc. is a medical device company, which focuses on technology to treat obesity and metabolic diseases. The company is headquartered in San Clemente, California and currently employs 47 full-time employees. The company went IPO on 2016-10-06. The firm is focused on offering an integrated portfolio of products and services that manage and treat obesity and metabolic disease. Its portfolio includes Lap-Band system, which provides minimally invasive, long-term treatment of obesity and is a safer surgical alternative to more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy. Its reshapecare virtual health coaching program is a reimbursed telehealth weight-management program that supports healthy lifestyle changes for all medically managed weight-loss patients. Its ReShape Marketplace is an online store, that provides a line of products for bariatric patients. Its ReShape Optimize supplement options include multivitamins, probiotics, calcium, vitamin D, protein and other therapeutic offerings to optimize health. Its ReShape Vest is an investigational, minimally invasive, laparoscopically implanted medical device.

View Section: Eyestock Rating